Three pharmaceutical and biotechnology companies announced the recent success of their respective funding rounds to support future efforts.

CEO Usama Malik is leading an exciting period of growth for Fore Biotherapeutics as the company evolves as a leader in precision oncology with its unique business model and ability to deliver the right therapies to currently underserved patients.

Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.

Merck KGaA and Artios Pharma Limited announced a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.

Bristol-Myers Squibb is taking aim at harnessing CRISPR-based solutions to treat certain cancers with a $65 million collaboration with Montreal-based Repare Therapeutics.

Eli Lilly is moving quickly to get the newly approved precision oncology treatment Retevmo for certain lung and thyroid cancers into the hands of patients.

Syapse, which accelerates precision medicine through insights derived from the company’s global health system network, announced a strategic collaboration with Pfizer Inc. to advance cancer outcomes research using real-world evidence toward the ultimate goal of improving patient health.

In April 2018, Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.